Why Teva’s Price Target Just Got Nudged Higher Teva Pharmaceutical Industries just saw its fair value estimate move from ...

Amid a reorganization campaign that’s breathed new life into hybrid generic and innovative medicines player Teva, the company is leaning into novel medicines and formulations more than ever and ...

As more drugmakers begin to report second-quarter earnings against the backdrop of the first material pharmaceutical tariff reveal from the Trump administration, Teva Pharmaceuticals isn’t sweating ...

Teva is transforming, with management delivering on profit growth, specialty drug expansion, and improving its balance sheet—yet the stock remains undervalued. Specialty products like AUSTEDO and ...

Teva Pharmaceutical Industries is launching its first global innovation platform, challenging startups to submit novel strategies to tackle seven pervasive industry hurdles that run the gamut from ...

Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.6 billion, has been navigating a complex landscape of legal ...

July 26 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab on Tuesday announced a $4.35 billion proposed nationwide settlement that could resolve thousands of lawsuits over the ...

Teva's Q4 earnings reveal significant headwinds, including declining U.S. generics revenue and rising costs in the API business, impacting overall profitability. Branded drugs like Austedo and Uzedy ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October. It achieved the golden cross in mid-September.

June 13 (Reuters) - Teva Pharmaceuticals (TEVA.TA), opens new tab sued rival drugmaker Corcept Therapeutics (CORT.O), opens new tab in federal court in San Francisco on Thursday, accusing it of ...

Shares of Teva -- a generic-drug maker with a history of losses and high leverage -- have rallied strongly. Pfizer and Merck, which make branded drugs, are financially strong and are rebuilding their ...

S&P upgraded Teva to BB+ and Moody's turned positive, citing falling leverage, stronger cash flow, and branded drug momentum that could support a future investment-grade rating.